Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Multicenter, Open-Label, Two-Arm, Phase III Neoadjuvant Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Patients With HER2-Positive Breast Cancer

Next Previous
Trial Profile

A Randomized, Multicenter, Open-Label, Two-Arm, Phase III Neoadjuvant Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Patients With HER2-Positive Breast Cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trastuzumab emtansine (Primary) ; Carboplatin; Docetaxel; Pertuzumab; Trastuzumab
  • Indications Early breast cancer; HER2 positive breast cancer; Male breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms KRISTINE
  • Sponsors Roche

Most Recent Events

  • 11 Jan 2023 Results published in the Breast Cancer Research
  • 11 Dec 2020 Results presented at the 43rd Annual San Antonio Breast Cancer Symposium
  • 14 Dec 2019 Results from a a systematic review and meta-analysis of phase 3 randomized controlled trials (MARIANNE, GATSBY, and KRISTINE), to determine the relative risk of peripheral neuropathy and peripheral sensory neuropathy associated with T-DM1 comparing to taxane-based regimens presented at the 42nd Annual San Antonio Breast Cancer Symposium.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top